Atea Pharmaceuticals, Inc.
AVIR Nasdaq
SEC CIK 1593899
Follow Atea Pharmaceuticals
Weekly email: filings, results
Net income
−$32.2M
+23.5% vs same quarter last year
EPS, diluted
−$0.40
+24.5% vs same quarter last year
Operating cash flow
−$28.9M
+28.5% vs same quarter last year
Operating income
−$34M
+25.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$158M |
| FY24 | −$168M |
| FY23 | −$136M |
| FY22 | −$116M |
| FY21 | $121M |
| FY20 | −$10.9M |
| FY19 | −$14M |
| FY18 | −$9.1M |
| FY17 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$122.9M |
| FY21 | −$87M |
| FY20 | $296.7M |
| FY19 | −$12.8M |
| FY18 | −$7.9M |
| FY17 | - |